A PHASE 1B DOUBLE-BLINDED PLACEBO-CONTROLLED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-06342674 (RN168) IN SUBJECTS WITH MULTIPLE SCLEROSIS (MS)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of subcutaneous infections of PF-06342674 in subjects with multiple sclerosis.
Description
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of subcutaneous infections of PF-06342674 in subjects with multiple sclerosis.
Details
| Condition | multiple sclerosis |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX4509 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.